Schwannoma

Centura Littleton Adventist Hospital First in Region to Use Innovative Non-Invasive Treatment for Brain Tumors

Retrieved on: 
Wednesday, January 25, 2023
Zap, Leeds Gamma Knife Centre, Skull, Patient, Dizziness, Cobalt, AdventHealth, Schwannoma, Radiosurgery, Rocky Mountains, Quality of life, Neurosurgery, Hearing loss, Brain, Health, Trigeminal neuralgia, Neck, Neoplasm, Centura, ZAPX, Head, Radiation, Skiing, Pain, Medical imaging

The outpatient procedure was first performed at Littleton Adventist Hospital on a 71-year-old man with a benign tumor that was causing symptoms affecting his quality of life.

Key Points: 
  • The outpatient procedure was first performed at Littleton Adventist Hospital on a 71-year-old man with a benign tumor that was causing symptoms affecting his quality of life.
  • Using Zap-X, Dr. Adair Prall with Neurosurgery One, a Centura clinic based at Littleton Adventist, was able to focus intense beams of radiation to treat the tumor while avoiding healthy surrounding tissue.
  • The technology can be used to treat many types of brain tumors and other conditions in the brain, head and neck.
  • Radiosurgery can be used to treat patients with trigeminal neuralgia, brain tumors, and other types of benign tumors such as acoustic neuromas.

Scientists Identify Hidden Factor That Help Pain after Fibromyalgia

Retrieved on: 
Monday, November 14, 2022
Tao, Gait, Postural orthostatic tachycardia syndrome, Awareness, Pain scale, Association, Grammatical mood, Academy of Family Physicians of India, NP-hardness, Parkinson's disease, Massage, Literature review, Fatigue, Report, Pinealectomy, Spondylosis, Prostate cancer, Neck pain, Pectus carinatum, Metastasis, Posture, Electromyography, Patient, Quality of life, Low back pain, Signs and symptoms, Back pain, Hidden, Multimedia, Dizziness, Diagnosis, Domestic violence, Breast cancer, Sleep, Knee pain, Deformity, Rehabilitation, NEW, Foramen magnum, ECP, American Journal, Thought, Headache, Bell's palsy, Schwannoma, Pharmaceutical industry, Medical device, Poultry, Birth control, Healthcare, Online shopping, Medicine, Fibromyalgia

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Scientists have identified treating cervical spondylosis helps patients with fibromyalgia stand up and live again.

Key Points: 
  • NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Scientists have identified treating cervical spondylosis helps patients with fibromyalgia stand up and live again.
  • A woman presented with a chronic headache, severe neck pain, shoulder pain, and back pain lasting for 2 years after experiencing domestic violence.
  • The widespread pain in fibromyalgia can lead to confused thinking and a lack of awareness of cervical spondylosis.
  • According to the researchers, this suggests chiropractic treatment blocked noxious inputs coming from pain sources, corrected pain thresholds, and lowered excitability, thereby eradicating fibromyalgia symptoms.

Neurosurgery One in Littleton, Colorado Treats First Patient with ZAP-X Gyroscopic Radiosurgery

Retrieved on: 
Monday, August 29, 2022
Oncology, Health, Medical Devices, Neurology, Hospitals, Surgery, Radiology, Schwannoma, Meningioma, Vestibular schwannoma, Nervous system, Skiing, CEO, Technology, Pain, Trigeminal neuralgia, Rocky Mountains, Brain, Edwards, Colorado, Dizziness, CO, WBRT, SRS, Radiation, Male, Radiation therapy, Quality of life, Multimedia, MD, TK, Stanford University, Hearing loss, ZAP, Patient, Medical imaging, Dentistry, Neurosurgery

ZAP Surgical Systems, Inc. today announced that Denver-based Neurosurgery One became the first provider in the Rocky Mountain region to treat patients using the ZAP-X Gyroscopic Radiosurgery platform.

Key Points: 
  • ZAP Surgical Systems, Inc. today announced that Denver-based Neurosurgery One became the first provider in the Rocky Mountain region to treat patients using the ZAP-X Gyroscopic Radiosurgery platform.
  • Neurosurgery One doctors are now performing stereotactic radiosurgery (SRS) using ZAP-X in an outpatient facility in the south Denver metro area of Littleton, Colorado.
  • View the full release here: https://www.businesswire.com/news/home/20220829005018/en/
    William (Bill) Lawson, of Edwards, CO, was the first patient in the Rocky Mountain region to undergo ZAP-X Gyroscopic Radiosurgery at Neurosurgery One in Littleton.
  • He was treated for an acoustic neuroma, a benign tumor on the main nerve leading between the inner ear and brain.

ZAP Surgical’s CEO and Stanford Neurosurgeon Receives Prestigious Janeway Medal, Recognized for Pioneering and Continued Advancement of Radiosurgical Brain Tumor Therapy

Retrieved on: 
Thursday, May 26, 2022
Oncology, Medical Devices, Health, Hospitals, Surgery, Radiology, Radium, Gamma, University, ZAP, Stanford University, Radiation, Stanford University School of Medicine, Hospital, American Radium Society, SRS, Radiosurgery, Multimedia, Memory, ARS, Patient, TK, Awareness, Karolinska Institute, Schwannoma, Radiation therapy, Technology, Faculty, Trigeminal neuralgia, Harvard College, LinkedIn, Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Isotope, Cancer, CEO, Medical device, Twitter, Neurosurgery

View the full release here: https://www.businesswire.com/news/home/20220525005269/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220525005269/en/
    Dr. John R. Adler, CEO of ZAP Surgical and Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University receiving the Janeway Medal.
  • (Photo: Business Wire)
    Since 1933, ARS has sponsored the Janeway Lecture in memory of Dr. Henry Janeway (1873-1921), a celebrated American physician and pioneer of radiation medicine.
  • As part of the Janeway Medal award, Dr. Adler was recognized for his early work in the radiosurgical treatment of spine tumors, acoustic neuromas, as well as trigeminal neuralgia.
  • In addition to being CEO of ZAP, Dr. Adler is Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University.

New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, European Society for Medical Oncology, SRS, U.S. Securities and Exchange Commission, Forward-looking statement, Investment, Population, Private Securities Litigation Reform Act, YouTube, Breast cancer, Twitter, Congress, NASDAQ, Radiation, Time, Patient, Security (finance), Cyberknife, Partnership, Neoplasm, Synchrony, Cancer, Risk, Lists of diseases, Radiation therapy, Schwannoma, LinkedIn, SEC, Tomotherapy, Technology, Medical imaging, Pharmaceutical industry, Facebook

SUNNYVALE, Calif., May 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKnife® and TomoTherapy® platforms, including the next-generation Radixact® System, to accurately and efficiently treat a wide variety of indications of all complexities. The data presented at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress held in Copenhagen, Denmark demonstrate how the advanced radiotherapy delivery platforms enable medical care teams to deliver truly personalized care aligned to the needs of each patient.

Key Points: 
  • The data shared at ESTRO show our customers are making this aspiration a reality and reinforces the impact they are making using our cutting-edge technologies," said Suzanne Winter, president of Accuray.
  • Studies indicate CyberKnife SRS can:
    Offer patients with acoustic neuromas a well-tolerated, effective regimen with excellent tumor control and acceptable hearing preservation .
  • Innovative Techniques: precise and efficient radiation dose delivery helps make it possible for a wide range of patients to receive treatment, including those with complex indications.
  • Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible.

Global Brain Tumor Drugs Market (2022 to 2031) - Featuring Pfizer, Shimadzu and Celgene Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 7, 2022
Health, Pharmaceutical, Benchmark, Neoplasm, Meningioma, Cisplatin, Glioblastoma, Radiation, Schwannoma, Temozolomide, Lists of diseases, Growth, Coronavirus, Patient, Chemotherapy, Glioma, Everolimus, Cancer, Prevalence, Brain, Medulloblastoma, Regeneration, National Brain Tumor Society, Life expectancy, Carmustine, Infection, PNET, Create, Astrocytoma, Anaplastic astrocytoma, Brain tumor, Marketing, Medical imaging, Oligodendroglioma, Bevacizumab

The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.

Key Points: 
  • The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.
  • The main types of drugs in brain tumor drugs are temozolomide, carmustine, cisplatin, bevacizumab, geftinib and erlotinib.
  • The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide.
  • Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market.

Global Microdebriders ENT Devices Market Analysis and Forecasts Report, 2015-2020 & 2021-2030 Featuring Medtronic, Olympus Corp, Stryker Corp, & KARL STORZ SE & Co KG - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 22, 2022
Surgery, Health, Medical Devices, ENT, Schwannoma, Vestibular nerve, Forecast model, Country, CMO, Tissue, SWOT, Industry, Review, Region, COVID-19, Market access, Epidemiology, Otorhinolaryngology, Risk management, Retail, Healthcare, Marketing

The "Microdebriders (ENT Devices) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microdebriders (ENT Devices) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • The model discusses in detail the impact of COVID-19 on Microdebriders market for the year 2020 and beyond.
  • Microdebriders are powered, rotating surgical tools used by otolaryngologists to cut and remove tissues and debris, typically within the sinus.
  • Global, Regional and Country level market specific insights:
    Qualitative market specific information is available with global trends further broken down into regional trends.

GE Healthcare Advances Precision Radiation Therapy Solutions with New Products, Partners and Solutions at #ASTRO21

Retrieved on: 
Monday, October 25, 2021
Medical Devices, Hospitals, Other Health, Biotechnology, Managed Care, Radiology, General Health, Pharmaceutical, Health, Oncology, Head, Brain, Meningioma, GE Healthcare, Thomas Edison, LinkedIn, Technology, Imaging, Cancer, Deep learning, Workflow, Schwannoma, Twitter, Patient, Revolution, Ecosystem, NYSE, RT, SNR, DICOM, Spectronic, Precision medicine, Profile, CEO, Mirada Studios, Multimedia, Motion, News, Solution, Artificial intelligence, Efficiency, ASTRO, AIR, Automation, Medical imaging, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20211025005723/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211025005723/en/
    GE Healthcare to showcase over 15 multi-modality radiation therapy solutions to improve patient-centered care and advance precision medicine.
  • #ASTRO21 (Photo: Business Wire)
    GE Healthcare aims to drive improved patient outcomes through cutting-edge multi-modality radiation therapy planning and guidance solutions.
  • GE Healthcares precision radiation oncology technologies, including those listed below, provide clinicians with images and information for precise tailoring of treatments.
  • Below are highlights that GE Healthcare will be showcasing at ASTRO 2021 from October 24th to 27th:
    Vysioneer VBrain: GE Healthcare is proud to announce its collaboration with Vysioneer.

RSNA: Deep Learning Model Classifies Brain Tumors with Single MRI Scan

Retrieved on: 
Wednesday, August 11, 2021
Linda, Classification, Brain, Statistics, Education, Association, MRI, Patient, Health, Radiological Society of North America, Lists of diseases, Schwannoma, Probability, Data, Mallinckrodt Institute of Radiology, Radiation, Meningioma, RSNA, Cancer, Washington University School of Medicine, Society, Artificial intelligence, Neoplasm, 2D, Convolutional neural network, Research, University, Deep learning, Perelman School of Medicine at the University of Pennsylvania, DRS, OAK, George Washington University School of Engineering and Applied Science, Pituitary adenoma, Medical imaging

According to Chakrabarty, machine and deep learning approaches using MRI data could potentially automate the detection and classification of brain tumors.

Key Points: 
  • According to Chakrabarty, machine and deep learning approaches using MRI data could potentially automate the detection and classification of brain tumors.
  • "Non-invasive MRI may be used as a complement, or in some cases, as an alternative to histopathologic examination," he said.
  • The researchers evaluated the performance of the model using data from both the internal and external MRI scans.
  • "These results suggest that deep learning is a promising approach for automated classification and evaluation of brain tumors," Chakrabarty said.

2021 Pipeline Insights on Vestibular Schwannoma - Featuring AstraZeneca, Recursion Pharmaceuticals and Takeda Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 4, 2021
Health, Biotechnology, Nervous system, Neurological disorders, Organ systems, Audiology, Occupational safety and health, Branches of biology, Otorhinolaryngology, Vestibular schwannoma, Tinnitus, Balance disorder, Dizziness, Schwannoma

The "Vestibular Schwannoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vestibular Schwannoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vestibular Schwannoma pipeline landscape.
  • Unilateral/asymmetric hearing loss and/or tinnitus and loss of balance/dizziness are early signs of a vestibular schwannoma.
  • Vestibular Schwannoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.